USFDAAug 6, 2026, 06:11 AM
Takeda's ORZEYFUL Approved by US FDA for Narcolepsy Type 1
AI Summary
Takeda announced that the U.S. FDA has approved ORZEYFUL (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1) in adults. This marks the first and only medicine to treat the underlying cause of NT1, offering a holistic approach beyond individual symptoms. The approval is based on positive Phase 3 clinical trial results demonstrating significant improvements across a range of NT1 symptoms. Takeda expects ORZEYFUL to be available in the U.S. following the Drug Enforcement Administration (DEA) scheduling process, which is anticipated within 90 days, and does not foresee a significant impact on its FY27 financial forecast.
Key Highlights
- U.S. FDA approved ORZEYFUL (oveporexton) for Narcolepsy Type 1 (NT1) in adults.
- ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist.
- It is the only medicine in the U.S. to treat the underlying cause of NT1 holistically.
- Approval based on comprehensive Phase 3 FirstLight and RadiantLight studies.
- Clinical trials showed significant improvements in excessive daytime sleepiness, cataplexy, and quality of life.
- Narcolepsy Type 1 affects an estimated 120,000 people in the U.S.
- Availability is expected following completion of the DEA scheduling process, anticipated within 90 days.
- The FDA approval is not expected to significantly impact the full year consolidated financial forecast for FY27.
Price Impact
More from TAK